Genetic Polymorphisms of DNA Repair Genes and their Influence on Paclitaxel based Chemotherapy Induced Toxicity Reactions in Breast Cancer Patients Authors: Kailas D Datkhile, Prajakta N Reur, Shivani R Kale, Rashmi A Gudur, Suresh J Bhosale, Anand K Gudur Published: 2024 ABSTRACT Background:Systemic chemotherapy constitutes an indispensable component of breast cancer (BC) management, where therapeutic drug combinations such as anthracyclines, platinum compounds, and taxanes form the cornerstone of standard treatment protocols. Although DNA repair genes are pivotal in cancer susceptibility, their specific roles in mediating acute or chronic toxicity outcomes induced by chemotherapy remain undetermined. Consequently, this study was planned to elucidate the impact of polymorphisms in base excision repair (BER) genes, including XRCC1, XRCC2, XRCC3, APE1, and hOGG1, on treatment response and toxicity outcomes in BC patients undergoing paclitaxel and doxorubicin-based chemotherapy within an Indian population.Methods:One hundred and four (104) BC patients receiving combined paclitaxel and doxorubicin chemotherapy were enrolled with documentation of both hematological and non-hematological toxicity reactions induced by the treatment. Genetic polymorphism of XRCC1, XRCC2, XRCC3, APE1, and hOGG1 genes was investigated using Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP) analysis. Results:Analysis of the demographic characteristics of BC patients revealed a significant association between mucositis and peripheral neuropathy with advancing age. An increased body mass index was also significantly correlated with hematological toxicities, such as neutropenia (p=0.022) and febrile neutropenia (p=0.048), as well as with peripheral neuropathy (p=0.001). Univariate logistic regression analysis demonstrated a significant association between the XRCC3 (Ser241Cys) polymorphism and peripheral neuropathy (OR=3.00, 95% CI: 1.29-6.95; p=0.010). Similarly, regression analysis indicated a significant association of APE-1 (Asp148Glu) polymorphism with febrile neutropenia (OR=3.55, 95% CI: 1.03-12.21; p=0.044) and chemotherapy-induced nausea and vomiting (CINV) (OR=4.19, 95% CI: 1.61-10.94; p=0.003) in BC patients treated with paclitaxel and Doxorubicin regimen. Conclusion:The findings from this study underscore the significant influence of genetic polymorphisms in XRCC3 (Ser241Cys) and APE-1 (Asp148Glu) on the acute toxicity effects induced by paclitaxel in BC patients. Introduction Breast cancer (BC) is the most common concern among women in both developing and developed countries and it ranks as the second leading cause of cancer-related deaths in women globally. Global cancer statistics showed that the overall burden of BC incidence and deaths is rising rapidly and that by 2040 there will be about 2964, 197 new BC cases with 31 % increase from 2,261,419 in year 2020 (11.7%) across the world [1]. BC is recognized as the principal and prominent cause of cancer related mortality in India, accounting 216,108 new cases (13.5 %) in 2022, with projections indicating a rise to 232, 832 cases by the year 2025 [2]. BC is a heterogeneous and multifactorial disease, wherein both established environmental factors and genetic determinants are scrutinized for their contributory roles in the pathogenesis of breast malignancy [3-4]. Numerous genetic and epigenetic modifications in DNA repair, tumor suppressor pathway genes contribute to increased risk of BC [5]. Genetic alterations of the genomic determinants resulted into uncertainty in normal cellular homeostasis, uninhibited cell growth, tumor development and finally in due course resulted into tumorigeneic process. The therapeutic approach to BC includes surgery, radiotherapy, hormone therapy, chemotherapy, targeted therapy, and immunotherapy. The best approach is chosen based on the type and stage of cancer, patient characteristics, and molecular features. Systemic chemotherapy in the form of adjuvant and neo-adjuvant chemotherapy has become an invasive treatment in BC management alongside surgery or radiotherapy, and is frequently used to improve the treatment outcomes [6-7]. Systemic treatment regimen plays a significant role in BC management wherein combinations of chemotherapy drugs with anthracyclines (Doxorubicin, Epirubicin), platinum (Cisplatin, Carboplatin) and taxanes (Paclitaxel, Docetaxel) forming the backbone of most schedules have been widely adopted in the standard therapeutics of BC [8-10]. Paclitaxel is a tetracyclic diterpenoid chemotherapeutic agent, utilized either alone [11-12] or in combination with other chemotherapy drugs to effectively treat advanced cancers. The paclitaxel treatment in combinations with cisplatin is documented in cervical cancer [13] head and neck cancer [14], carboplatin in gastric or esophageal cancer [15]. Almost all chemotherapy agents including paclitaxel can cause severe aftereffects (acute toxicities) in patients where haematological and non-hematological adverse reactions are prominent [16-19]. The most prevalent toxicities such as, alopecia, nausea and vomiting, mucositis, neutropenia, leukopenia, anemia, hypersensitivity reactions, arthralgia, myalgia, and peripheral neuropathy are caused by paclitaxel. Despite recent advances, predicting the outcomes of paclitaxel chemotherapy cannot be generalized for all patients. This is because paclitaxel-treated cells may upregulate DNA repair mechanisms, allowing them to repair drug-induced DNA damage and survive the toxic effects. Genetic polymorphisms affecting DNA repair capacity can influence the efficacy and toxicity of chemotherapy drugs. There are reports on the influence of BER gene polymorphisms on platinum and gemcitabine-based chemotherapy response in non-small cell lung cancer patients [20-23]. The XRCC1 rs25487 and rs1799782 SNPs have been studied for their effectiveness in hematological toxicities in response to platinum based chemptherapy in NSCLC [24] esophagus [25] and colorectal cancer [26]. However, evidence on the association of DNA repair gene polymorphisms with treatment outcomes in BC patients treated with paclitaxel alone or in combination with other drugs, has not been established. It was assumed that genetic variability in DNA repair pathway genes might be connected to chemotherapy-induced toxicity reactions in BC patients receiving paclitaxel chemotherapy. Understanding the pharmacogenetic susceptibility of patients with genetic variants in DNA repair genes is crucial for assessing their role in drug toxicity profiles. This brings into interest to explore the genetic control of DNA repair genes on normal tissue during paclitaxel chemotherapy in BC patients. Therefore, in this study, we decided to verify association of single nucleotide polymorphisms (SNPs) of DNA repair genes and their impact on treatment related outcomes including toxicities in BC patients treated with paclitaxel based chemotherapy. To address this, we investigated the polymorphisms of XRCC1 (Arg194Trp, Arg280His, Arg399Gln), XRCC2 (Arg188His), XRCC3 (Ser241Cys), APE-1 (Asp148Glu), hOGG1 (Ser326Cys) genes and their association with chemotherapy induced toxicity reactions in BC patients from Maharashtra. Materials and Methods Study Design Cross-sectional, Observational,Analytical study was carried out at Department of Molecular Biology and Genetics in association with Department of Oncology of Krishna Hospital and Medical Research Center, Karad, Maharashtra, India. Patient enrollment and clinical information One hundred and four (104) patients with histologically confirmed non-metastatic breast cancer, visiting to Krishna Hospital and Medical Research Centre for the treatment at Department of Oncology of Krishna Vishwa Vidyapeeth (Deemed to be Univesrsity) Karad were enrolled in this study. Patients were enrolled in this study based upon selection criterias including; histopathological confirmation, no metastasis. The patients with no pathological diagnosis, incomplete treatment, incomplete followup, patients with other comorbidities were excuuded from the study. This detailed clinical profile encompassing with demographic characteristics, chemotherapy regimens, and follow-up details, was systematically recorded. Chemotherapy treatment regimen follow up and toxicity assessment Upon enrollment the patients were administered with four cycles of paclitaxel every three weeks thereafter four cycles of Doxorubicn. After the first cycle of chemotherapy, patients were monitored between Day 10 and Day 14 for chemotherapy-related toxicities. The patients were followed for one year at regular intervals to assess treatment response and toxicity. Patients were informed about potential adverse effects and advised to report any serious side effects or attend scheduled follow-ups, with these incidents graded per the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03. Patients were routinely tested for blood and urine parameters, including complete blood count, renal function, and liver function before each chemotherapy cycle, to monitor health and identify chemotherapy-induced side effects. Both hematological toxicities (e.g., anemia, neutropenia) and non-hematological toxicities (e.g., mucositis, chemotherapy-induced nausea/vomiting (CINV), fatigue, body ache, peripheral neuropathy) were recorded and classified according to NCI-CTC criteria and graded from 0 to 4. For comparison of BC patients with toxicity reactions (>1 grade) were considered as chemo-sensitive groups and compared to patients with ≤ 1 grade reactions. Blood sample collection, genomic DNA extraction and genotyping assays Five milliliter (mL) of intravenous blood from each patient was collected in sterile EDTA containing vacutainer after receiving informed consent. Genomic DNA extraction was carried out from the peripheral blood sample using HipurA®Blood genomic DNA miniprep purification kit (Cat no. MB504-250PR) (HiMedia Laboratories) following the manufacturer’s instructions. The genotyping assay of DNA repair genes XRCC1, XRCC2, XRCC3, APE-1, and hOGG1 was conducted using PCR-RFLP method. The PCR amplification for polymorphism confirmation was performed in 20 µL reaction mixtures containing 1X PCR buffer, 0.2 mM each dNTP, 10 pmol each primer (IDT technologies), 1U Taq DNA polymerase (GeNei, Merck Bioscience), and 100 ng of purified genomic DNA. The primer sequence used to amplify XRCC1 (Arg194Trp); forward primer (FP): 5’-GCC AGG GCC CCT CCT TCA A-3’; reverse primer (RP): 5’-TAC CCT CAG ACC CAC GAG T-3’ XRCC1 (Arg280His); FP:5’-CCA GCT CCA ACT CGT ACC-3’; RP: 5’ ATG AGG TGC GTG CTG TCC-3’, XRCC1 (Arg399Gln); FP: 5’-CAG TGG TGC TAA CCT AAT C-3’ ; RP: 5’-AGT AGT CTG CTG GCT CTG G-3, XRCC2 (Arg188His); FP: 5’-GTT GCT GCC ATG CCT TAC A-3’ ; RP: 5’-TGT AGT CAC CCA TCT CTC TGC-3’, XRCC3 (Ser241Cys); FP: 5’-GGT CGA GTG ACA GTC CAA AC-3’ ; RP: 5’-TGC AAC GGC TGA GGG TCT T- 3’, APE-1 (Asp148Glu; FP:5’-CTG TTT CAT TTC TAT AGG CTA-3’; RP:5’- AGG AAC TTG CGA AAG GCT TC-3’, hOGG1(Ser326Cys); FP:5’- CTG TTC AGT GCC GAC CTG CGC CGA -3’; RP: 5’ ATC TTG TTG TGC AAA CTG AC -3’. Subsequently, the PCR-amplified products of XRCC1 (cd-194: 485 bp, cd-280: 257 bp, cd-399: 871 bp), XRCC2 (cd-188: 290 bp), XRCC3 (cd-241: 455 bp), APE1 (cd-148: 164 bp), and hOGG1 (cd-326: 247bp) were digested overnight with restriction enzymes PvuII, RsaI, NciI, HphI, NlaIII, BfaI, MboII respectively.The digestion reactions were then analyzed via agarose gel electrophoresis in Tris-Acetate-EDTA (TAE) buffer, stained with ethidium bromide (10 mg/mL), and visualized under a UV transilluminator. The results were subsequently photographed using a gel documentation system (BioRad Laboratories). Statistical analysis The Odds Ratio (OR) and corresponding 95% confidence intervals (CI) were calculated to determine the association between the grade of acute toxicity and selected gene polymorphisms. A univariate logistic regression model assessed the impact of each genetic polymorphism in DNA repair genes on the incidence of toxicity (grades 0-1 vs. 2-4), with results expressed as ORs and 95% CIs. The clinical severity of post-chemotherapy adverse effects was defined by hematological and non-hematological toxicity reactions exceeding grade 1. Statistical significance was set at p < 0.05, and all analyses were performed using SPSS Software (Version 21.0). Results Demographic, clinical characteristics and chemotherapy induced toxicities in study subjects In this study, 104 BC patients were enrolled, with ages ranging from 27 to 78 years and a mean age of 50.30 years. Among these patients, 44 (42.31%) were over 50 years old, with 35 (66.35%) women having a BMI of ≤ 25, and 35 (33.65%) women having a BMI greater than 25. A total of 85 (81.73%) women received adjuvant chemotherapy, while 19 were treated with neoadjuvant chemotherapy. Immunohistochemical analysis revealed that 48 patients were ER/PR positive, 53 patients were ER/PR negative, and 44 patients had triple-negative breast cancer. Clinical TNM staging showed that 47 patients were at stage III or IV, and histopathological TNM staging indicated the same for another 47 patients. All 104 patients initially received Paclitaxel followed by Doxorubicin, and 43 patients were also administered Tamoxifen in conjunction with combined chemotherapy. After a one-year follow-up post-chemotherapy, 49 patients showed no evidence of disease, 35 patients experienced metastasis, four patients had a recurrence of the disease, and two patients succumbed to it. Significant hematological toxicities, including anemia (84.62%) with grade >1 toxicity, were observed following Paclitaxel chemotherapy, whereas neutropenia and febrile neutropenia did not show a significant increase. Notably, non-hematological toxicities with grade >1 were significantly elevated in patients treated with Paclitaxel. Chemotherapy-induced nausea and vomiting and fatigue were noted with grade >1 toxicity in 94.23% of patients, 85.58% experienced body ache with grade >1 toxicity, and 75.96% suffered from significantly higher rates of peripheral neuropathy. The demographic, clinical, and histopathological characteristics were correlated with paclitaxel-based chemotherapy-induced toxicities in BC patients, revealing no association of anemia with age, BMI, or clinical and pathological TNM stages III and IV. However, non-hematological toxicities demonstrated a significant correlation with the age of BC patients over 50 years, where mucositis (p=0.002) and peripheral neuropathy (p=0.009) showed a marked increase. Analyzing the impact of BMI on chemotherapy-induced acute toxicities in patients treated with paclitaxel revealed a significant correlation of BMI >25 with hematological toxicities such as neutropenia (p=0.022) and febrile neutropenia (p=0.048), as well as peripheral neuropathy (p=0.001). The analysis of clinical TNM stage with grade >III indicated a significant association with mucositis (p=0.047), while histopathological TNM grade >III showed an association with neutropenia (p=0.027) in patients treated with the combination of paclitaxel and Doxorubicin chemotherapy. Analysis of genotype distribution of XRCC1, XRCC2, XRCC3, APE-1 and hOGG-1 gene polymorphisms and paclitaxel induced toxicity effects in BC patients The regression analysis of polymorphisms in DNA repair genes, including XRCC1, XRCC2, XRCC3, APE-1, and hOGG1, and their association with acute hematological and non-hematological toxicities induced by combined paclitaxel and Doxorubicin chemotherapy are detailed in Table 1 to Table 7. Hematological and non-hematological toxicities were classified into grade ≤1 or >1 based on NCI-CTC criteria. Among the 104 BC patients primarily treated with paclitaxel followed by Doxorubicin, 90 patients exhibited G1-G4 grade toxicities, while 14 patients displayed G0 grade anemia toxicity. Severe neutropenia (G1-G4) was observed in 28 patients, and febrile neutropenia (G1-G4) in 14 patients. Following paclitaxel chemotherapy, severe non-hematological toxicities with grade G1-G4 were noted in 56 patients with mucositis, 100 patients with chemotherapy-induced nausea and vomiting (CINV) and fatigue, 91 patients with body aches, and 81 patients with peripheral neuropathy. The univariate logistic regression analysis of genetic polymorphisms in the XRCC1 gene, specifically at codon 194 of exon 6, did not reveal any significant association with hematological or non-hematological toxicities in BC patients treated with paclitaxel chemotherapy (Table 1). Similarly, the Arg280His polymorphism of the XRCC1 gene at exon 9 was not correlated with any hematological or non-hematological toxicity reactions, such as mucositis, chemotherapy-induced nausea and vomiting (CINV), body ache, or peripheral neuropathy (Table 2). No significant differences were observed in the incidence of severe toxicities, including mucositis, CINV, fatigue, and body ache, in Paclitaxel-treated breast cancer patients with the 280His genotype of the XRCC1 gene. Furthermore, the XRCC1 gene polymorphism at codon 399 of exon 10 did not show any significant correlation with hematological or non-hematological acute toxicities from Paclitaxel chemotherapy in BC patients (Table 3). In the analysis of the Arg188His polymorphism of the XRCC1 gene and its association with paclitaxel-induced acute toxicities in BC patients, no significant association was found between genetic variants of the XRCC2 gene and the development of increased acute hematological or non-hematological toxicities from paclitaxel-based chemotherapy. The logistic regression analysis of XRCC2 gene polymorphisms and their association with acute toxicities in BC patients following paclitaxel chemotherapy is presented in Table 4. The findings from the univariate regression analysis examining the association of the XRCC3 gene Ser241Cys polymorphism at exon 7 with both hematological and non-hematological toxicities induced by paclitaxel-based chemotherapy in BC patients are detailed in Table 5. The odds ratios with 95% confidence intervals for patients with the combined heterozygous and recessive Ser/Cys + Cys/Cys genotypes indicated a significant association with peripheral neuropathy (OR=3.00, 95% CI: 1.29-6.95; p=0.010). However, the XRCC3 Ser241Cys polymorphism did not show any significant correlation with other hematological or non-hematological toxicities. Similarly, the ASP148Glu polymorphism of the APE-1 gene was studied for its association with Paclitaxel-induced chemotherapy toxicity, yielding noteworthy results. There was a significant association of the heterozygous Asp/Glu genotype of APE-1 with febrile neutropenia (OR=3.55, 95% CI: 1.03-12.21; p=0.044) and chemotherapy-induced nausea and vomiting (OR=4.19, 95% CI: 1.61-10.94; p=0.003) in BC patients treated with paclitaxel chemotherapy (Table 6). Additionally, the hOGG1 (Ser326Cys) polymorphism at codon 326 of exon 7, was assessed for its association with acute toxicities induced by paclitaxel chemotherapy, but this analysis showed no significant association with either hematological or non-hematological toxicities (Table 7). Discussion Genetic factors significantly influence an individual’s susceptibility to chemotherapy-induced adverse reactions, and understanding these factors can aid in mitigating the side effects of chemotherapy. While chemotherapeutic agents are designed for target-specific actions, the mechanisms of many chemotherapy drugs remain inadequately understood. Therefore, comprehending the genetic diversity of patients undergoing chemotherapy is crucial, as it determines pharmacogenetic susceptibility to both the efficacy and toxicity of these drugs. A substantial number of patients experience severe acute or late toxicity reactions without clear justification for the severity. However, this unpredictability can largely be attributed to the genetic makeup of individuals, which may account for their clinical sensitivity to chemotherapy and negatively impact their quality of life. Numerous studies have indicated that genetic variability, particularly in genes involved in DNA repair pathways, is associated with chemotherapy-induced toxicity [22, 27-31]. Some SNPs of DNA repair genes have been elucidated for their role in therapeutic response to certain chemotherapy treatments. However, other SNPs might partially accounted for the interindividual variability observed in response to chemotherapeutic drugs [24, 32-33]. The toxicities related to chemotherapeutic drugs, which are associated with genetic polymorphisms in DNA repair genes, can provide valuable insights into predicting clinical responses and outcomes of selected chemotherapy regimens [34]. In this context, polymorphisms of BER genes, including XRCC1 and XRCC2, have been extensively studied for their significant associations with both the response and toxicity of chemotherapy [35]. Several studies have highlighted the influence of XRCC1 gene (Arg399Gln) polymorphism on clinical outcomes in patients with colorectal cancer [36-37] and ovarian cancer [28] in response to platinum-based chemotherapy. Additionally, other studies have demonstrated an increased risk of chemotherapy-induced hematological toxicities in non-small cell lung cancer (NSCLC) patients harboring the XRCC1 gene polymorphism when treated with platinum-based chemotherapy [22, 38-40]. Similarly, another study revealed a significant association between the XRCC1 (Arg399Gln) polymorphism and an elevated risk of hematological toxicities in NSCLC patients in response to a combination of cisplatin and gemcitabine chemotherapy [41]. Furthermore, the variant (Gln/Gln) genotype of the XRCC1 (Arg399Gln) polymorphism was associated with an increased risk of gastrointestinal toxicities in lung cancer patients treated with cisplatin-based chemotherapy [42]. However, other studies on DNA repair gene polymorphisms did not demonstrate any chemotoxic response in NSCLC [43] and pharyngeal cancer patients [44] when treated with platinum- or taxane-based chemotherapy. In a similar vein, XRCC1 Arg399Gln polymorphisms showed no association with chemotherapy-induced toxicities in lung cancer patients treated with cisplatin-based chemotherapy [42] and in NSCLC cases receiving a combination of platinum and paclitaxel or docetaxel-based chemotherapy [45]. Thus, numerous studies have delved into the genetic variations within these genes and their implications for cancer susceptibility; however, there remains a paucity of information concerning SNPs in BER genes and their correlation with chemotherapy treatment responses and outcomes across a range of cancers, including BC. Consequently, it becomes imperative to identify genetic polymorphisms in critical DNA repair genes, such as XRCC1, XRCC2, XRCC3, APE-1, and hOGG1, to enhance the efficacy of chemotherapeutic interventions and mitigate the associated toxicity in BC patients. Paclitaxel chemotherapy, when combined with Doxorubicin, is a standard treatment regimen for BC management. However, there are no reports on paclitaxel-related chemotherapy-induced toxicity reactions in BC or other cancer types. In this context, our study explored the association of genetic polymorphisms in BER genes with chemotherapy-induced toxicity reactions. The results demonstrated significant association between the combined heterozygous and recessive genotypes of the XRCC3 (Ser241Cys) polymorphism and peripheral neuropathy in BC patients treated with paclitaxel and doxorubicin which was not reported earlier. Similarly, the heterozygous genotype of the APE-1 gene polymorphism showed a significant positive influence on both hematological toxicity, such as febrile neutropenia, and non-hematological toxicity, such as chemotherapy-induced nausea and vomiting (CINV), in BC patients administered a combination of paclitaxel followed by doxorubicin. In contrast, our investigation found no significant correlation between the XRCC1 (Arg399Gln) polymorphism, as well as its variations at codons 194 and 280, and the incidence of paclitaxel-induced toxicities in this patient cohort. Moreover, the hOGG1 (Ser326Cys) polymorphisms similarly exhibited no discernible association with the adverse toxicity responses to paclitaxel chemotherapy in BC patients. In conclusion, the results of this study underscore a significant correlation between the XRCC3 (Ser241Cys) polymorphism and the occurrence of peripheral neuropathy induced by paclitaxel and doxorubicin chemotherapy in BC patients from the studied population. Additionally, the APE1 polymorphic variant 148Glu genotype exhibited a strong association with febrile neutropenia and chemotherapy-induced nausea and vomiting (CINV) following paclitaxel treatment. To the best of our knowledge, this is the first investigation of its kind to elucidate the relationship between XRCC3 and APE1 gene polymorphisms and chemotherapy-related toxicities in BC patients subjected to paclitaxel and doxorubicin therapy. These findings may serve as a foundational reference for future studies aiming to establish clinical correlations between various therapeutic modalities and their toxicological impacts in BC treatment. Table 1Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1, codon-194, exon-6) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicitiesXRCC1ToxicityToxicityOR (95% CI)pvalueGenotypesGrade ≤1Grade >1AnemiaArg/Arg72101 (Reference)Arg/Trp1641.80.50-6.470.368Trp/Trp201.380.06-30.790.838Arg/Trp+Trp/Trp1841.60.44-5.690.468NeutropeniaArg/Arg71111 (Reference)Arg/Trp1820.710.14-3.520.682Trp/Trp201.240.05-27.590.89Arg/Trp+Trp/Trp2020.640.13-3.150.588Febrile neutropeniaArg/Arg71111 (Reference)Arg/Trp1910.330.04-2.790.315Trp/Trp201.240.05-27.590.89Arg/Trp+Trp/Trp2110.30.03-2.520.271MucositisArg/Arg37451 (Reference)Arg/Trp1280.540.20-1.480.236Trp/Trp110.820.04-13.590.891Arg/Trp+Trp/Trp1390.560.21-1.470.247CINVArg/Arg60231 (Reference)Arg/Trp1450.930.30-2.880.902Trp/Trp112.60.15-43.470.504Arg/Trp+Trp/Trp1561.040.36-3.010.937FatigueArg/Arg58241 (Reference)Arg/Trp1550.80.26-2.460.704Trp/Trp200.470.02-10.310.637Arg/Trp+Trp/Trp1750.710.23-2.140.544BodyacheArg/Arg43381 (Reference)Arg/Trp1290.840.32-2.230.739Trp/Trp111.130.06-18.720.931Arg/Trp+Trp/Trp13100.870.34-2.210.77Peripheral neuropathyArg/Arg54291 (Reference)Arg/Trp1540.4960.15-1.630.249Trp/Trp147.440.79-69.770.078Arg/Trp+Trp/Trp1650.580.19-1.740.335OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1, codon-194, exon-6) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Table 2Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1, cd-280,exon-9) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicities XRCC1 ToxicityToxicityOR (95% CI)pvalueGenotypesGrade ≤1Grade >1AnemiaArg/Arg3851 (Reference)Arg/His4891.420.44-4.600.554His/His400.770.03-16.510.871Arg/His+His/His5291.310.40-4.240.646NeutropeniaArg/Arg4041 (Reference)Arg/His4881.660.46-5.940.431His/His313.330.27-40.030.342Arg/His+His/His5191.760.50-6.140.372Febrile neutropeniaArg/Arg3941 (Reference)Arg/His5071.360.37-4.990.638His/His313.250.27-39.040.352Arg/His+His/His5381.470.41-5.230.55MucositisArg/Arg4301 (Reference)Arg/His51610.980.60-200.490.105His/His409.660.17-548.420.27Arg/His+His/His55610.180.55-185.870.117CINVArg/Arg30131 (Reference)Arg/His43140.750.30-1.820.527His/His310.760.07-8.100.827Arg/His+His/His46150.750.31-1.800.523FatigueArg/Arg32121 (Reference)Arg/His40161.060.44-2.570.885His/His343.550.69-18.280.128Arg/His+His/His43171.050.44-2.510.905BodyacheArg/Arg23211 (Reference)Arg/His29271.010.46-2.240.961His/His400.120.006-2.390.165Arg/His+His/His33270.890.41-1.950.782Peripheral neuropathyArg/Arg30161 (Reference)Arg/His37170.860.37-1.980.726His/His310.620.06-6.500.694Arg/His+His/His40180.840.37-1.920.685OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1, cd-280,exon-9) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Table 3Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1,cd-399, exon-10) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicities XRCC1 ToxicityToxicityOR (95% CI)p valueGenotypesGrade ≤1Grade >1AnemiaArg/Arg3791 (Reference)Arg/Gln4440.370.10-1.310.124Gln/Gln821.020.18-5.690.975Arg/Gln+Gln/Gln5260.470.15-1.440.19NeutropeniaArg/Arg4161 (Reference)Arg/Gln4171.160.36-3.770.796Gln/Gln900.330.01-6.490.470Arg/Gln+Gln/Gln5070.950.29-3.070.941Febrile neutropeniaArg/Arg4171 (Reference)Arg/Gln4150.710.20-2.430.591Gln/Gln910.650.07-5.960.704Arg/Gln+Gln/Gln5060.700.21-2.250.553MucositisArg/Arg4521 (Reference)Arg/Gln4352.610.48-14.210.265Gln/Gln900.950.04-21.600.978Arg/Gln+Gln/Gln5252.160.40-11.690.370CINVArg/Arg31161 (Reference)Arg/Gln36120.640.26-1.570.335Gln/Gln810.24002-2.100.199Arg/Gln+Gln/Gln44130.570.24-1.350.205FatigueArg/Arg34131 (Reference)Arg/Gln35130.970.39-2.390.949Gln/Gln631.300.28-6.010.730Arg/Gln+Gln/Gln41161.020.43-2.410.962BodyacheArg/Arg26221 (Reference)Arg/Gln22241.280.57-2.890.539Gln/Gln640.780.19-3.150.736Arg/Gln+Gln/Gln28281.180.54-2.550.671Peripheral neuropathyArg/Arg30191 (Reference)Arg/Gln32140.690.29-1.610.394Gln/Gln720.450.08-2.400.351Arg/Gln+Gln/Gln39160.640.28-1.460.298OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC1,cd-399, exon-10) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Table 4Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC2, cd 188, exon-3) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicities XRCC2 ToxicityToxicityOR (95% CI)p valueGenotypesGrade ≤1Grade >1AnemiaArg/Arg73111 (Reference)Arg/His1631.240.31-4.970.757His/His00NCArg/His+His/His1631.240.31-4.970.757NeutropeniaArg/Arg71111 (Reference)Arg/His2110.310.03-2.520.271His/His00NCArg/His+His/His2110.310.03-2.520.271Febrile neutropeniaArg/Arg72111 (Reference)Arg/His2010.320.03-2.680.298His/His00NCArg/His+His/His2010.320.03-2.680.298MucositisArg/Arg7751 (Reference)Arg/His2110.730.08-6.520.782His/His00NCArg/His+His/His2110.730.08-6.520.782CINVArg/Arg63211 (Reference)Arg/His1282.000.71-5.550.183His/His00NCArg/His+His/His1282.000.71-5.550.183FatigueArg/Arg60231 (Reference)Arg/His1561.040.36-3.010.937His/His00NCArg/His+His/His1561.040.36-3.010.937BodyacheArg/Arg44391 (Reference)Arg/His12100.940.36-2.410.898His/His00NCArg/His+His/His12100.940.36-2.410.898Peripheral neuropathyArg/Arg56271 (Reference)Arg/His1471.030.37-2.860.944His/His00NCArg/His+His/His1471.030.37-2.860.944OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Effect of Genetic Polymorphisms of DNA Repair Gene (XRCC2, cd 188, exon-3) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Table 5Effect of Genetic Polymorphisms of DNA repair Gene (XRCC3, cd-241, exon-7) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicities in Breast Cancer PatientsToxicities XRCC3 ToxicityToxicityOR (95% CI)p valueGenotypesGrade ≤1Grade >1AnemiaSer/Ser5561 (Reference)Ser/Cys3272.000.61-6.480.245Cys/Cys214.580.36-58.350.240Ser/Cys+Cys/Cys3582.090.67-6.550.203NeutropeniaSer/Ser5561 (Reference)Ser/Cys3371.940.60-6.280.266Cys/Cys214.580.36-58.350.240Ser/Cys+Cys/Cys3582.090.67-6.550.203Febrile neutropeniaSer/Ser5741 (Reference)Ser/Cys3283.560.99-12.760.051Cys/Cys301.820.08-41.110.704Ser/Cys+Cys/Cys3583.250.91-11.620.068MucositisSer/Ser5731 (Reference)Ser/Cys3821.000.15-6.261.000Cys/Cys401.820.08-41.110.704Ser/Cys+Cys/Cys4220.90.144-5.650.914CINVSer/Ser45171 (Reference)Ser/Cys27121.170.48-2.830.717Cys/Cys211.320.11-15.560.823Ser/Cys+Cys/Cys29131.180.50-2.800.696FatigueSer/Ser43171 (Reference).Ser/Cys29121.040.43-2.510.918Cys/Cys211.260.10-14.880.851Ser/Cys+Cys/Cys31131.060.45-2.490.892BodyacheSer/Ser31281 (Reference)Ser/Cys23190.910.41-2.020.825Cys/Cys122.210.19-25.770.525Ser/Cys+Cys/Cys24210.960.44-2.100.936Peripheral neuropathySer/Ser46141 (Reference)Ser/Cys22192.831.20-6.680.017*Cys/Cys126.570.55-77.990.135Ser/Cys+Cys/Cys23213.001.29-6.950.010*OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05); *, Indicates significant Odds Ratio (p<0.05) Effect of Genetic Polymorphisms of DNA repair Gene (XRCC3, cd-241, exon-7) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicities in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05); *, Indicates significant Odds Ratio (p<0.05) Table 6Effect of Genetic Polymorphisms of DNA Repair Gene (APE1, cd-148, exon-5) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicitiesAPE-1ToxicityToxicityOR (95% CI)pvalueGenotypesGrade ≤1Grade >1AnemiaAsp/Asp6981 (Reference)Asp/Glu2062.580.80-8.330.111Glu/Glu102.720.10-72.350.548Asp/Glu+Glu/Glu2162.460.76-7.900.129NeutropeniaAsp/Asp7371 (Reference)Asp/Glu1852.890.82-10.190.097Glu/Glu103.260.12-87.480.48Asp/Glu+Glu/Glu1952.740.78-9.610.114Febrile neutropeniaAsp/Asp7161 (Reference)Asp/Glu2063.551.03-12.210.044*Glu/Glu103.660.13-99.390.44Asp/Glu+Glu/Glu2163.380.98-11.580.052MucositisAsp/Asp7431 (Reference)Asp/Glu2333.210.60-17.040.169Glu/Glu107.090.24-207.430.255Asp/Glu+Glu/Glu2433.080.58-16.300.185CINVAsp/Asp62161 (Reference)Asp/Glu12134.191.61-10.940.003*Glu/Glu101.260.04-32.440.888Asp/Glu+Glu/Glu13133.871.50-9.960.005*FatigueAsp/Asp58211 (Reference)Asp/Glu1681.380.51-3.690.52Glu/Glu100.90.03-23.120.952Asp/Glu+Glu/Glu1781.290.48-3.450.599BodyacheAsp/Asp41351 (Reference)Asp/Glu14131.080.45-2.620.851Glu/Glu100.380.01-6.86)0.567Asp/Glu+Glu/Glu15131.010.42-2.420.972Peripheral neuropathyAsp/Asp54231 (Reference)Asp/Glu15111.720.68-4.310.246Glu/Glu100.770.03-19.670.876Asp/Glu+Glu/Glu16111.610.64-4.000.302 Effect of Genetic Polymorphisms of DNA Repair Gene (APE1, cd-148, exon-5) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients Table 7Effect of Genetic Polymorphisms of DNA Repair Gene (hOGG1, cd-326, exon-7) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer PatientsToxicitieshOGG1ToxicityToxicityOR (95% CI)pvalueGenotypesGrade ≤1Grade >1AnemiaSer/Ser3751 (Reference)Ser/Cys3871.3260.39-4.680.622Cys/Cys1520.980.17-5.650.988Ser/Cys+Cys/Cys5391.250.38-4.050.702NeutropeniaSer/Ser3861 (Reference)Ser/Cys3940.640.16-2.480.528Cys/Cys1431.350.29-6.170.692Ser/Cys+Cys/Cys5370.830.26-2.680.764Febrile neutropeniaSer/Ser3931 (Reference)Ser/Cys39620.46-8.570.35Cys/Cys1432.780.50-15.440.241Ser/Cys+Cys/Cys5392.20.56-8.690.257MucositisSer/Ser4121 (Reference)Ser/Cys4131.50.23-9.450.666Cys/Cys1611.280.10-15.130.844Ser/Cys+Cys/Cys5741.430.25-8.230.682CINVSer/Ser31111 (Reference)Ser/Cys32131.140.44-2.930.778Cys/Cys1251.170.33-4.090.801Ser/Cys+Cys/Cys44181.150.47-2.770.751FatigueSer/Ser30121 (Reference)Ser/Cys32131.010.40-2.570.973Cys/Cys1340.760.20-2.830.693Ser/Cys+Cys/Cys45170.940.39-2.250.897BodyacheSer/Ser22201 (Reference)Ser/Cys22221.10.47-2.560.825Cys/Cys1260.550.17-1.740.309Ser/Cys+Cys/Cys34280.90.41-1.980.805Peripheral neuropathySer/Ser29111 (Reference)Ser/Cys27181.750.70-4.380.227Cys/Cys1450.940.27-3.230.923Ser/Cys+Cys/Cys41231.470.62-3.500.373OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Effect of Genetic Polymorphisms of DNA Repair Gene (hOGG1, cd-326, exon-7) on Risk of Paclitaxel Chemotherapy Induced Hematological and Non-Hematological Toxicity Reactions in Breast Cancer Patients OR, Odds ratio; CI, Confidence interval; p value determined based on χ2; Level of significance (p< 0.05) Author Contribution Statement Authors Contribution: Concept: KDD, RAG, SJB Design: KDD, RAG, Experimental Studies: PNR, SRK Clinical studies: RAG, AKG, Data analysis: KDD, RAG, Statistical analysis: KDD, Manuscript preparation: KDD, RAG, SJB All authors read and approved the final manuscript.